RxDoctor Payments Data

Joseph Bender, DPM

Podiatrist · McAllen, TXNPI 1265436828

Payments from drug & device makers

$2,241in general payments, 2019–2025

Across 115 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$779
  • Organogenesis Inc.$753
  • Osiris Therapeutics Inc.$210
  • Amgen$133
  • Melinta Therapeutics, LLC$59
  • Paratek Pharmaceuticals, Inc.$52
  • plus $256 from 9 others

What the payments were for

  • Speaking & faculty fees$743%
  • Food & beverage$2,16797%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,241 in reported general payments places this provider in the 50th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$1,655,104
Medicare patients
313
Services billed
3,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.73$44,920
Clotrimazole162$4,668
Ciclopirox34$1,276
Gentamicin Sulfate16$728
Doxycycline Monohydrate29$537
Ammonium Lactate21$427
Terbinafine Hcl25$238
Amoxicillin68$228
Doxycycline Hyclate20$177
Levofloxacin60$168
Ciprofloxacin Hcl16$95
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$66
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$779$44,92073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 470 podiatrist providers in Texas.

Other podiatrist in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →